Meeting Banner
Abstract #0142

Cardiac 31P MRS in breast cancer patients undergoing chemotherapy

Gillian Macnaught1,2, Christopher Rodgers3, Martin Denvir4, Olga Oikonomidou5,6, Annette Cooper1, William Clarke3, Heather McVicars6, Larry Hayward6, Saeed Mirsadraee1, and Scott Semple1,4

1Clinical Research Imaging Centre, University of Edinburgh, Edinburgh, United Kingdom, 2the MRC Centre for inflammation Research, University of Edinburgh, Edinburgh, United Kingdom, 3RDM Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom, 4BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom, 5Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom, 6Edinburgh Cancer Centre, NHS Lothian, Edinburgh, United Kingdom

Anthracyclines are chemotherapy agents widely used to treat cancer but that can also induce cardiotoxicity. Techniques are required to provide an earlier warning of cardiotoxicity before irreversible myocardial damage. 9 subjects were recruited to this on-going 31P MRS study to detect changes in cardiac energetics of breast cancer patients undergoing chemotherapy. Between pre- and mid-chemotherapy four subjects experienced a greater than 20% decrease in their cardiac PCr/ATP ratio, 1 subject experienced a 13.8% decrease in left ventricular ejection fraction (LVEF) and all had increased troponin levels. Ultimately this study aims to determine whether changes in PCr/ATP precede changes in LVEF.

This abstract and the presentation materials are available to members only; a login is required.

Join Here